What one share of ImmunityBio holds
ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.
ImmunityBio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.17 |
|---|---|
| Profit | −$0.99 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.29 |
| Cash and investments | $0.34 |
| Book value | −$0.99 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | $0.75 | −$2.57 | $0.00 | −$0.84 | — | −$4.71 |
| 2014 | $0.08 | −$0.75 | $0.03 | −$0.69 | — | $6.98 |
| 2015 | $0.00 | −$3.31 | $0.03 | −$0.39 | — | $4.38 |
| 2016 | $0.00 | −$1.47 | $0.08 | −$0.55 | — | $3.58 |
| 2017 | $0.00 | −$1.20 | $0.43 | −$1.04 | — | $2.77 |
| 2018 | $0.00 | −$1.22 | $0.17 | −$0.97 | — | $1.85 |
| 2019 | $0.01 | −$0.43 | $0.01 | −$0.43 | — | — |
| 2020 | $0.00 | −$0.59 | $0.00 | −$0.46 | — | −$0.31 |
| 2021 | $0.00 | −$0.89 | $0.09 | −$0.79 | — | −$0.61 |
| 2022 | $0.00 | −$1.04 | $0.20 | −$1.04 | — | −$1.06 |
| 2023 | $0.00 | −$1.15 | $0.06 | −$0.78 | — | −$0.88 |
| 2024 | $0.02 | −$0.62 | $0.01 | −$0.57 | — | −$0.57 |
| 2025 | $0.12 | −$0.38 | $0.00 | −$0.34 | — | −$0.49 |
Common questions about ImmunityBio
How much does one share of ImmunityBio earn?
Over the last 12 months, ImmunityBio lost $0.99 for each share on $0.17 of sales.
Does ImmunityBio pay a dividend?
ImmunityBio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is ImmunityBio’s book value per share?
ImmunityBio’s book value is negative (−$0.99 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of ImmunityBio have?
Each share of ImmunityBio has $0.34 of cash and investments, as of June 30, 2026.
What is ImmunityBio’s free cash flow per share?
−$0.29 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has ImmunityBio bought back shares?
ImmunityBio’s share count rose about 115300% from 2013 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.